Ascletis Pharma-B (01672) announced that on November 4, 2026, the company granted share options to 42 participants to subscribe for a total of 1.8 million ordinary shares of the company with a par value of US$0.0001 per share. The exercise price of the granted share options is HK$4.923 per share, with a validity period of 10 years.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.